Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by KIYOSHI KOSHIDA
Novel HER2 Selective Tyrosine Kinase Inhibitor, TAK-165, Inhibits Bladder, Kidney and Androgen-Independent Prostate Cancer in Vitro and in Vivo
International Journal of Urology
Urology
Related publications
P2.13-32 TAK-788 Is a Novel and Potent Tyrosine Kinase Inhibitor With Selective Activity Against EGFR/HER2
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
HER2-Targeted Hybrid Peptide That Blocks HER2 Tyrosine Kinase Disintegrates Cancer Cell Membrane and Inhibits Tumor Growth in Vivo
Molecular Cancer Therapeutics
Cancer Research
Oncology
Lapatinib, a Dual EGFR and HER2 Kinase Inhibitor, Selectively Inhibits HER2-Amplified Human Gastric Cancer Cells and Is Synergistic With Trastuzumab in Vitro and in Vivo
Clinical Cancer Research
Cancer Research
Oncology
PCC0208027, a Novel Tyrosine Kinase Inhibitor, Inhibits Tumor Growth of NSCLC by Targeting EGFR and HER2 Aberrations
Scientific Reports
Multidisciplinary
MP470, a Novel Receptor Tyrosine Kinase Inhibitor, in Combination With Erlotinib Inhibits the HER Family/Pi3k/Akt Pathway and Tumor Growth in Prostate Cancer
BMC Cancer
Cancer Research
Oncology
Genetics
Lupeol, a Novel Androgen Receptor Inhibitor: Implications in Prostate Cancer Therapy
Clinical Cancer Research
Cancer Research
Oncology
Retraction: Psoralidin, an Herbal Molecule, Inhibits Phosphatidylinositol 3-Kinase-Mediated Akt Signaling in Androgen-Independent Prostate Cancer Cells
Cancer Prevention Research
Medicine
Cancer Research
Oncology
Hedgehog Signalling in Androgen Independent Prostate Cancer
European Urology
Urology
CC-223, a Potent and Selective Inhibitor of mTOR Kinase: In Vitro and in Vivo Characterization
Molecular Cancer Therapeutics
Cancer Research
Oncology
